F. Widjaja Inflammatory Bowel Disease Institute, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, California, USA.
Gut. 2023 Nov;72(11):2068-2080. doi: 10.1136/gutjnl-2023-329689. Epub 2023 Apr 20.
Perianal Crohn's disease (pCD) occurs in up to 40% of patients with CD and is associated with poor quality of life, limited treatment responses and poorly understood aetiology. We performed a genetic association study comparing CD subjects with and without perianal disease and subsequently performed functional follow-up studies for a pCD associated SNP in ().
Immunochip-based meta-analysis on 4056 pCD and 11 088 patients with CD from three independent cohorts was performed. Serological and clinical variables were analysed by regression analyses. Risk allele of rs4151651 was introduced into human CFB plasmid by site-directed mutagenesis. Binding of recombinant G252 or S252 CFB to C3b and its cleavage was determined in cell-free assays. Macrophage phagocytosis in presence of recombinant CFB or serum from risk, or protective CD or healthy subjects was assessed by flow cytometry.
Perianal complications were associated with colonic involvement, OmpC and ASCA serology, and serology quartile sum score. We identified a genetic association for pCD (rs4151651), a non-synonymous SNP (G252S) in , in all three cohorts. Recombinant S252 CFB had reduced binding to C3b, its cleavage was impaired, and complement-driven phagocytosis and cytokine secretion were reduced compared with G252 CFB. Serine 252 generates a de novo glycosylation site in CFB. Serum from homozygous risk patients displayed significantly decreased macrophage phagocytosis compared with non-risk serum.
pCD-associated rs4151651 in is a loss-of-function mutation that impairs its cleavage, activation of alternative complement pathway, and pathogen phagocytosis thus implicating the alternative complement pathway and CFB in pCD aetiology.
肛周克罗恩病(pCD)可发生于高达 40%的 CD 患者中,与生活质量差、治疗应答有限以及发病机制尚不完全清楚有关。我们对患有和不患有肛周疾病的 CD 患者进行了一项遗传关联研究,并随后对与 pCD 相关的 SNP(rs4151651)进行了功能随访研究。
对来自三个独立队列的 4056 名 pCD 患者和 11088 名 CD 患者进行了基于免疫芯片的荟萃分析。通过回归分析分析血清学和临床变量。通过定点诱变将 rs4151651 的风险等位基因引入到人类 CFB 质粒中。在无细胞测定中测定重组 G252 或 S252 CFB 与 C3b 的结合及其切割。通过流式细胞术评估存在重组 CFB 或来自 pCD 风险、保护性或健康受试者的血清时巨噬细胞的吞噬作用。
肛周并发症与结肠受累、OmpC 和 ASCA 血清学以及血清学四分位和评分有关。我们在所有三个队列中都发现了 pCD(rs4151651)的遗传关联,这是一种位于 中的非同义 SNP(G252S)。与 G252 CFB 相比,重组 S252 CFB 与 C3b 的结合减少,其切割受损,补体驱动的吞噬作用和细胞因子分泌减少。丝氨酸 252 在 CFB 中产生了一个新的糖基化位点。与非风险血清相比,来自纯合风险患者的血清显示出明显降低的巨噬细胞吞噬作用。
位于 的 pCD 相关 rs4151651 是一种功能丧失突变,可损害其切割、替代补体途径的激活以及病原体吞噬作用,从而暗示替代补体途径和 CFB 参与了 pCD 的发病机制。